Literature DB >> 3326213

Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation.

R J Stead1, I Skypala, M E Hodson, J C Batten.   

Abstract

In an open, randomised crossover study enteric coated microspheres of pancreatin were compared with a standard preparation of enteric coated pancreatin over two consecutive 28 day treatment periods in 23 adults with steatorrhoea due to cystic fibrosis. Lipase intake was equal to the patients' previous requirements and was the same during the two months. Patients performed 72 hour faecal collections at the end of each month and completed diary cards daily throughout. Comparison of the month of treatment with enteric coated microspheres with the month of standard enteric coated tablets showed a significant increase in body weight on microsphere capsules (p less than 0.02). There was also a reduced frequency of bowel actions (p less than 0.001) and abdominal pain (p less than 0.05), and improvement in stool character (p less than 0.001) on microsphere capsules. Faecal fat excretion was reduced by 44% with the microsphere capsules (p less than 0.01), and 86% of patients showed an increased coefficient of fat absorption (mean increase 13%, 95% confidence limits 6.5-19.1%; p less than 0.001). Eighty one per cent of patients preferred microsphere capsules of the two treatments. Thus enteric coated microsphere capsules are more effective in treating steatorrhoea in cystic fibrosis than standard enteric coated tablets.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3326213      PMCID: PMC460823          DOI: 10.1136/thx.42.7.533

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules.

Authors:  E P DiMagno; J R Malagelada; V L Go; C G Moertel
Journal:  N Engl J Med       Date:  1977-06-09       Impact factor: 91.245

2.  Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency.

Authors:  P T Regan; J R Malagelada; E P DiMagno; S L Glanzman; V L Go
Journal:  N Engl J Med       Date:  1977-10-20       Impact factor: 91.245

3.  Steatorrhea and azotorrhea and their relation to growth and nutrition in adolescents and young adults with cystic fibrosis.

Authors:  A Lapey; J Kattwinkel; P A Di Sant'Agnese; L Laster
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

4.  Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine.

Authors:  R Gow; R Bradbear; P Francis; R Shepherd
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

5.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

6.  Relative underweight in cystic fibrosis and its prognostic value.

Authors:  R Kraemer; A Rüdeberg; B Hadorn; E Rossi
Journal:  Acta Paediatr Scand       Date:  1978-01

7.  Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature.

Authors:  P A di Sant'agnese; P B Davis
Journal:  Am J Med       Date:  1979-01       Impact factor: 4.965

8.  Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis.

Authors:  P L Zentler-Munro; D R Fine; J C Batten; T C Northfield
Journal:  Gut       Date:  1985-09       Impact factor: 23.059

Review 9.  Cystic fibrosis and malnutrition.

Authors:  H P Chase; M A Long; M H Lavin
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

10.  Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis.

Authors:  R Shepherd; W G Cooksley; W D Cooke
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

View more
  21 in total

Review 1.  Control of malabsorption in cystic fibrosis.

Authors:  J M Littlewood; S P Wolfe
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

3.  Energy content of stools in normal healthy controls and patients with cystic fibrosis.

Authors:  J L Murphy; S A Wootton; S A Bond; A A Jackson
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

Review 4.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

5.  Two enteric coated microspheres in cystic fibrosis.

Authors:  J Williams; A MacDonald; P H Weller; J Fields; H Pandov
Journal:  Arch Dis Child       Date:  1990-06       Impact factor: 3.791

6.  In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract.

Authors:  Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

Review 7.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

Review 8.  Nutritional management of the infant with cystic fibrosis.

Authors:  M R Green; E Buchanan; L T Weaver
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

Review 9.  The problems with high dose pancreatic enzyme preparations.

Authors:  C J Taylor
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

10.  A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis.

Authors:  I M Bowler; S P Wolfe; H M Owens; T A Sheldon; J M Littlewood; M P Walters
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.